Cover Image

Intraoperative end-tidal carbon dioxide levels are not associated with recurrence-free survival after elective pancreatic cancer surgery: a retrospective cohort study

<sec><title>Background</title><p>Intraoperative end-tidal carbon dioxide concentrations (EtCO<sub>2</sub>) values are associated with recurrence-free survival after colorectal cancer surgery. However, it is unknown if similar effects can be observed after other su...

Full description

Saved in:
Bibliographic Details
Main Authors: Dehne, Sarah (Author) , Kirschner, Lina (Author) , Klotz, Rosa (Author) , Kilian, Samuel (Author) , Michalski, Christoph (Author) , Hackert, Thilo (Author) , Büchler, Markus W. (Author) , Weigand, Markus A. (Author) , Larmann, Jan (Author)
Format: Article (Journal)
Language:English
Published: 11 September 2024
In: Frontiers in medicine
Year: 2024, Volume: 11, Pages: 1-9
ISSN:2296-858X
DOI:10.3389/fmed.2024.1442283
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fmed.2024.1442283
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1442283/full
Get full text
Author Notes:Sarah Dehne, Lina Kirschner, Rosa Klotz, Samuel Kilian, Christoph W. Michalski, Thilo Hackert, Markus W. Büchler, Markus A. Weigand and Jan Larmann
Description
Summary:<sec><title>Background</title><p>Intraoperative end-tidal carbon dioxide concentrations (EtCO<sub>2</sub>) values are associated with recurrence-free survival after colorectal cancer surgery. However, it is unknown if similar effects can be observed after other surgical procedures. There is now evidence available for target EtCO<sub>2</sub> and its relation to surgical outcomes following pancreatic cancer surgery.</p></sec><sec><title>Methods</title><p>In this single-center, retrospective cohort study, we analyzed 652 patients undergoing elective resection of pancreatic cancer at Heidelberg University Hospital between 2009 and 2016. The entire patient cohort was sorted in ascending order based on mean intraoperative EtCO<sub>2</sub> values and then divided into two groups: the high-EtCO<sub>2</sub> group and the low-EtCO2 group. The pre-specified primary endpoint was the assessment of recurrence-free survival up to the last known follow-up. Cardiovascular events, surgical site infections, sepsis, and reoperations during the hospital stay, as well as overall survival were pre-specified secondary outcomes.</p></sec><sec><title>Results</title><p>Mean EtCO<sub>2</sub> was 33.8 mmHg ±1.1 in the low-EtCO<sub>2</sub> group vs. 36.8 mmHg ±1.9 in the high-EtCO<sub>2</sub> group. Median follow-up was 2.6 (Q1:1.4; Q3:4.4) years. Recurrence-free survival did not differ among the high and low-EtCO<sub>2</sub> groups [HR = 1.043 (95% CI: 0.875-1.243), log rank test: <italic>p</italic> = 0.909]. Factors affecting the primary endpoint were studied via Cox analysis, which indicated no correlation between mean EtCO<sub>2</sub> levels and recurrence-free survival [Coefficient −0.004, HR = 0.996 (95% CI:0.95-1.04); <italic>p</italic> = 0.871]. We did not identify any differences in the secondary endpoints, either.</p></sec><sec><title>Conclusions</title><p>During elective pancreatic cancer surgery, anesthesiologists should set EtCO<sub>2</sub> targets for reasons other than oncological outcome until conclusive evidence from prospective, multicenter randomized controlled trials is available.</p></sec>
Item Description:Gesehen am 21.11.2024
Physical Description:Online Resource
ISSN:2296-858X
DOI:10.3389/fmed.2024.1442283

Similar Items